Schizophrenia
Conditions
Brief summary
The primary endpoint is the change from baseline in glycated haemoglobin A1c (HbA1c)
Detailed description
Changes in body weight, hip, waist circumference, blood pressure, heart rate, plasma insulin, C-peptide, glucagon, incretin hormones, lipid profile, proteomics and bone markers, insulin sensitivity, beta-cell function (evaluated by HOMA. Body composition and bone density evaluated by DXA-scan), liver function (transaminases), liver fibrosis (fibrosis-4 (FIB-4) score), alcohol, tobacco and drug use, preference for sweet and fatty candy, psychopathology, activity and quality of life.
Interventions
Sponsors
Psykiatrisk Center Kobenhavn
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the change from baseline in glycated haemoglobin A1c (HbA1c) | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in body weight, hip, waist circumference, blood pressure, heart rate, plasma insulin, C-peptide, glucagon, incretin hormones, lipid profile, proteomics and bone markers, insulin sensitivity, beta-cell function (evaluated by HOMA. Body composition and bone density evaluated by DXA-scan), liver function (transaminases), liver fibrosis (fibrosis-4 (FIB-4) score), alcohol, tobacco and drug use, preference for sweet and fatty candy, psychopathology, activity and quality of life. | — |
Countries
Denmark
Outcome results
None listed